Jing Sun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jing Sun has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Bob S. Carter
Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
11 shared publications - Bryan D. Choi
Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
11 shared publications - Daniel P. Cahill
Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
11 shared publications - Eric P. Grewal
Department of Neurosurgery, Massachusetts General Hospital , Boston, MA
11 shared publications - Julie J. Miller
Translational Neuro-Oncology Laboratory, Brain Tumor Research Center, Massachusetts General Hospital and Harvard Medical School , Boston (T.N., H.W., D.P.C., J.J.M.); , Boston (T.N., H.W., D.P.C.); , Tokyo (T.N.); , Boston (N.A.J., C.I.W.); , Boston (M.M.-L., M.L.S.); , Rehovot (I.T.); , Cambridge (M.L.S.); , Boston (M.L.S.); , Scarborough (C.L.-E.); , Boston (J.J.M.)
11 shared publications - Leland G.K. Richardson
Brain Tumor Immunotherapy Laboratory, Massachusetts General Hospital, Boston, Massachusetts. 1
11 shared publications
Latest Publications
- Open Access
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Mutant IDH Modulates Suppressive Myeloid Populations in Malignant Glioma
Supplementary Figure 2. Quantitation of additional myeloid cell subtypes in murine IDH-wildtype and IDH-mutant glioma
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Mutant IDH Modulates Suppressive Myeloid Populations in Malignant Glioma
Supplementary Figure 2. Quantitation of additional myeloid cell subtypes in murine IDH-wildtype and IDH-mutant glioma
- Open Access
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Mutant IDH Modulates Suppressive Myeloid Populations in Malignant Glioma
Supplementary Table 1. Clinical characteristics of glioma patients and samples
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Mutant IDH Modulates Suppressive Myeloid Populations in Malignant Glioma
Supplementary Table 1. Clinical characteristics of glioma patients and samples
- Open Access
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Mutant IDH Modulates Suppressive Myeloid Populations in Malignant Glioma
Supplementary Figure 3. Effect of IDH inhibition on intratumoral macrophage population in murine IDH-mutant glioma
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Mutant IDH Modulates Suppressive Myeloid Populations in Malignant Glioma
Supplementary Figure 3. Effect of IDH inhibition on intratumoral macrophage population in murine IDH-mutant glioma
- Open Access
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Mutant IDH Modulates Suppressive Myeloid Populations in Malignant Glioma
Supplementary Figure 3. Effect of IDH inhibition on intratumoral macrophage population in murine IDH-mutant glioma
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Mutant IDH Modulates Suppressive Myeloid Populations in Malignant Glioma
Supplementary Figure 3. Effect of IDH inhibition on intratumoral macrophage population in murine IDH-mutant glioma
- Open Access
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Mutant IDH Modulates Suppressive Myeloid Populations in Malignant Glioma
Supplementary Table 1. Clinical characteristics of glioma patients and samples
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Mutant IDH Modulates Suppressive Myeloid Populations in Malignant Glioma
Supplementary Table 1. Clinical characteristics of glioma patients and samples
- Open Access
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Data from Mutant IDH Modulates Suppressive Myeloid Populations in Malignant Glioma
Purpose:Mutations in the isocitrate dehydrogenase (IDH) genes IDH1 and IDH2 have critical diagnostic and prognostic significance in diffuse gliomas. Neomorphic mutant IDH activity has been previously implicated in T-cell suppression; however, the effects of IDH mutations on intratumoral myeloid populations remain underexplored. In this study, we investigate the influence of IDH status on the myeloid compartment using human glioma specimens and preclinical models.Experimental Design:We performed RNA sequencing and quantitative immunofluorescence on newly diagnosed, treatment-naive IDH-mutant grade 4 astrocytoma and IDH-wild-type (IDH-WT) glioblastoma (GBM) specimens. We also generated a syngeneic murine model, comparing transcriptomic and cell-level changes in paired isogenic glioma lines that differ only in IDH mutational status.Results:Among patient samples, IDH-mutant tumors displayed an underrepresentation of suppressive myeloid transcriptional signatures, which was confirmed at the cellular level with decreased numbers of intratumoral M2-like macrophages and myeloid-derived suppressor cells. Introduction of the mutant IDH enzyme into murine glioma was sufficient to recapitulate the transcriptomic and cellular shifts observed in patient samples.Conclusions:We provide transcriptomic and cellular evidence that mutant IDH is associated with a quantitative reduction of suppressive myeloid cells in gliomas and that introduction of the mutant enzyme is sufficient to result in corresponding cellular changes using an in vivo preclinical model. These data advance our understanding of high-grade gliomas by identifying key myeloid cell populations that are reprogrammed by mutant IDH and may be targetable through therapeutic approaches.
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Mutant IDH Modulates Suppressive Myeloid Populations in Malignant Glioma
Purpose:Mutations in the isocitrate dehydrogenase (IDH) genes IDH1 and IDH2 have critical diagnostic and prognostic significance in diffuse gliomas. Neomorphic mutant IDH activity has been previously implicated in T-cell suppression; however, the effects of IDH mutations on intratumoral myeloid populations remain underexplored. In this study, we investigate the influence of IDH status on the myeloid compartment using human glioma specimens and preclinical models.Experimental Design:We performed RNA sequencing and quantitative immunofluorescence on newly diagnosed, treatment-naive IDH-mutant grade 4 astrocytoma and IDH-wild-type (IDH-WT) glioblastoma (GBM) specimens. We also generated a syngeneic murine model, comparing transcriptomic and cell-level changes in paired isogenic glioma lines that differ only in IDH mutational status.Results:Among patient samples, IDH-mutant tumors displayed an underrepresentation of suppressive myeloid transcriptional signatures, which was confirmed at the cellular level with decreased numbers of intratumoral M2-like macrophages and myeloid-derived suppressor cells. Introduction of the mutant IDH enzyme into murine glioma was sufficient to recapitulate the transcriptomic and cellular shifts observed in patient samples.Conclusions:We provide transcriptomic and cellular evidence that mutant IDH is associated with a quantitative reduction of suppressive myeloid cells in gliomas and that introduction of the mutant enzyme is sufficient to result in corresponding cellular changes using an in vivo preclinical model. These data advance our understanding of high-grade gliomas by identifying key myeloid cell populations that are reprogrammed by mutant IDH and may be targetable through therapeutic approaches.
- Open Access
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Mutant IDH Modulates Suppressive Myeloid Populations in Malignant Glioma
Supplementary Figure 1. Flow cytometry gating strategy for quantifying murine intratumoral myeloid cell populations
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Mutant IDH Modulates Suppressive Myeloid Populations in Malignant Glioma
Supplementary Figure 1. Flow cytometry gating strategy for quantifying murine intratumoral myeloid cell populations
- Open Access
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Data from Mutant IDH Modulates Suppressive Myeloid Populations in Malignant Glioma
Purpose:Mutations in the isocitrate dehydrogenase (IDH) genes IDH1 and IDH2 have critical diagnostic and prognostic significance in diffuse gliomas. Neomorphic mutant IDH activity has been previously implicated in T-cell suppression; however, the effects of IDH mutations on intratumoral myeloid populations remain underexplored. In this study, we investigate the influence of IDH status on the myeloid compartment using human glioma specimens and preclinical models.Experimental Design:We performed RNA sequencing and quantitative immunofluorescence on newly diagnosed, treatment-naive IDH-mutant grade 4 astrocytoma and IDH-wild-type (IDH-WT) glioblastoma (GBM) specimens. We also generated a syngeneic murine model, comparing transcriptomic and cell-level changes in paired isogenic glioma lines that differ only in IDH mutational status.Results:Among patient samples, IDH-mutant tumors displayed an underrepresentation of suppressive myeloid transcriptional signatures, which was confirmed at the cellular level with decreased numbers of intratumoral M2-like macrophages and myeloid-derived suppressor cells. Introduction of the mutant IDH enzyme into murine glioma was sufficient to recapitulate the transcriptomic and cellular shifts observed in patient samples.Conclusions:We provide transcriptomic and cellular evidence that mutant IDH is associated with a quantitative reduction of suppressive myeloid cells in gliomas and that introduction of the mutant enzyme is sufficient to result in corresponding cellular changes using an in vivo preclinical model. These data advance our understanding of high-grade gliomas by identifying key myeloid cell populations that are reprogrammed by mutant IDH and may be targetable through therapeutic approaches.
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Mutant IDH Modulates Suppressive Myeloid Populations in Malignant Glioma
Purpose:Mutations in the isocitrate dehydrogenase (IDH) genes IDH1 and IDH2 have critical diagnostic and prognostic significance in diffuse gliomas. Neomorphic mutant IDH activity has been previously implicated in T-cell suppression; however, the effects of IDH mutations on intratumoral myeloid populations remain underexplored. In this study, we investigate the influence of IDH status on the myeloid compartment using human glioma specimens and preclinical models.Experimental Design:We performed RNA sequencing and quantitative immunofluorescence on newly diagnosed, treatment-naive IDH-mutant grade 4 astrocytoma and IDH-wild-type (IDH-WT) glioblastoma (GBM) specimens. We also generated a syngeneic murine model, comparing transcriptomic and cell-level changes in paired isogenic glioma lines that differ only in IDH mutational status.Results:Among patient samples, IDH-mutant tumors displayed an underrepresentation of suppressive myeloid transcriptional signatures, which was confirmed at the cellular level with decreased numbers of intratumoral M2-like macrophages and myeloid-derived suppressor cells. Introduction of the mutant IDH enzyme into murine glioma was sufficient to recapitulate the transcriptomic and cellular shifts observed in patient samples.Conclusions:We provide transcriptomic and cellular evidence that mutant IDH is associated with a quantitative reduction of suppressive myeloid cells in gliomas and that introduction of the mutant enzyme is sufficient to result in corresponding cellular changes using an in vivo preclinical model. These data advance our understanding of high-grade gliomas by identifying key myeloid cell populations that are reprogrammed by mutant IDH and may be targetable through therapeutic approaches.
- Open Access
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Mutant IDH Modulates Suppressive Myeloid Populations in Malignant Glioma
Supplementary Figure 1. Flow cytometry gating strategy for quantifying murine intratumoral myeloid cell populations
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Mutant IDH Modulates Suppressive Myeloid Populations in Malignant Glioma
Supplementary Figure 1. Flow cytometry gating strategy for quantifying murine intratumoral myeloid cell populations
- Open Access
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Mutant IDH Modulates Suppressive Myeloid Populations in Malignant Glioma
Supplementary Figure 2. Quantitation of additional myeloid cell subtypes in murine IDH-wildtype and IDH-mutant glioma
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Mutant IDH Modulates Suppressive Myeloid Populations in Malignant Glioma
Supplementary Figure 2. Quantitation of additional myeloid cell subtypes in murine IDH-wildtype and IDH-mutant glioma